MA32438B1 - Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant - Google Patents

Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant

Info

Publication number
MA32438B1
MA32438B1 MA33084A MA33084A MA32438B1 MA 32438 B1 MA32438 B1 MA 32438B1 MA 33084 A MA33084 A MA 33084A MA 33084 A MA33084 A MA 33084A MA 32438 B1 MA32438 B1 MA 32438B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
compositions containing
antagonist activity
releasing factor
corticotropin releasing
Prior art date
Application number
MA33084A
Other languages
Arabic (ar)
English (en)
Inventor
Katsumi Kobayashi
Kazuyoshi Aso
Takafumi Takai
Takuto Kojima
Kazuyuki Tokumaru
Michiyo Mochizuki
Yasutaka Hoashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32438B1 publication Critical patent/MA32438B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne un composé représenté par la formule (i') dans laquelle x est de l'azote ou crx, rx est de l'hydrogène, etc., r1 est un groupe hydrocarbure éventuellement substitué, etc., r2 est un groupe hydrocarbure éventuellement substitué, etc., le noyau a est un noyau hétérocyclique de 5 à 8 chaînons, etc., et y1, y2 et y3 sont chacun du carbone ou de l'azote éventuellement substitués, etc.. L'invention concerne également un sel ou un promédicament dudit composé, présentant une activité antagoniste sur le récepteur crf, ainsi que leur utilisation.
MA33084A 2008-01-22 2010-08-13 Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant MA32438B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US655408P 2008-01-22 2008-01-22
PCT/JP2009/051299 WO2009093747A1 (fr) 2008-01-22 2009-01-21 Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
MA32438B1 true MA32438B1 (fr) 2011-07-03

Family

ID=40637104

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33084A MA32438B1 (fr) 2008-01-22 2010-08-13 Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant

Country Status (26)

Country Link
US (2) US8785460B2 (fr)
EP (1) EP2240485B1 (fr)
JP (1) JP5431341B2 (fr)
KR (1) KR20100130596A (fr)
CN (1) CN101981031A (fr)
AR (1) AR070218A1 (fr)
AU (1) AU2009206936A1 (fr)
BR (1) BRPI0907230A2 (fr)
CA (1) CA2712347A1 (fr)
CL (1) CL2009000116A1 (fr)
CO (1) CO6230982A2 (fr)
CR (1) CR11636A (fr)
DO (1) DOP2010000226A (fr)
EA (1) EA201070876A1 (fr)
EC (1) ECSP10010414A (fr)
GE (1) GEP20125637B (fr)
IL (1) IL207074A0 (fr)
MA (1) MA32438B1 (fr)
MX (1) MX2010008039A (fr)
NZ (1) NZ587215A (fr)
PE (1) PE20091439A1 (fr)
SG (1) SG189803A1 (fr)
TW (1) TW200936591A (fr)
UY (1) UY31604A1 (fr)
WO (1) WO2009093747A1 (fr)
ZA (1) ZA201005340B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
WO2010093425A1 (fr) 2009-02-11 2010-08-19 Sepracor Inc. Agonistes et antagonistes inverses de l'histamine h3 et leurs procédés d'utilisation
WO2011031818A2 (fr) * 2009-09-11 2011-03-17 Sepracor Inc. Agonistes inverses et antagonistes du récepteur h3 de l'histamine et leurs procédés d'utilisation
MY166866A (en) 2011-08-18 2018-07-24 Nippon Shinyaku Co Ltd Heterocyclic derivative and pharmaceutical drug
EP2825541B1 (fr) 2012-03-16 2016-06-22 Vitae Pharmaceuticals, Inc. Modulateurs du récepteur x du foie
JP6114815B2 (ja) 2012-03-16 2017-04-12 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 肝臓ｘレセプターモジュレーター
WO2014165816A1 (fr) 2013-04-05 2014-10-09 North Carolina Central University Composés utiles dans le traitement de troubles métaboliques et leur synthèse
CN103435618B (zh) * 2013-08-22 2016-03-23 中国药科大学 一种合成稠杂环化合物的方法
KR20170005868A (ko) * 2014-05-23 2017-01-16 액티브 바이오테크 에이비 S100-저해제로서 유용한 새로운 화합물
CN105859630B (zh) * 2015-01-22 2019-01-18 北京大学 一种咪唑酮衍生物的合成方法及应用
EP3356369B1 (fr) 2015-10-01 2022-05-04 Idemitsu Kosan Co., Ltd Benzimidazol[1,2-a]benzimidazole à groupes triazine pour diodes électroluminescentes organiques
EP3150604B1 (fr) 2015-10-01 2021-07-14 Idemitsu Kosan Co., Ltd. Groupes benzimidazolo [1,2-a] benzimidazoles portant des benzimidazolo [1,2-a] benzimidazolyles, groupes carbazolyles, groupes benzofuranes ou benzothiophènes pour diodes électroluminescentes organiques
WO2018220513A1 (fr) * 2017-05-31 2018-12-06 Alembic Pharmaceuticals Limited Procédé amélioré de préparation d'acide obéticholique

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS516993A (en) 1974-07-05 1976-01-20 Dainippon Pharmaceutical Co Adeninjudotaino seiho
HUP0303653A3 (en) 2000-12-28 2006-05-29 Ono Pharmaceutical Co Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
EP1637521B1 (fr) 2003-06-23 2013-06-19 Ono Pharmaceutical Co., Ltd. Nouveau compose heterocyclique tricyclique
US7897607B2 (en) 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
WO2008051533A2 (fr) 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Composés de benzimidazole
EP2125753A1 (fr) 2006-12-29 2009-12-02 Takeda Pharmaceutical Company Limited Composes heterocycliques lies par fusion developpant une activite antagoniste au crf
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
CL2009000119A1 (es) 2008-01-22 2010-03-05 Boehringer Ingelheim Int Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.

Also Published As

Publication number Publication date
BRPI0907230A2 (pt) 2019-09-24
CR11636A (es) 2010-11-04
EP2240485A1 (fr) 2010-10-20
PE20091439A1 (es) 2009-10-19
SG189803A1 (en) 2013-05-31
TW200936591A (en) 2009-09-01
KR20100130596A (ko) 2010-12-13
AR070218A1 (es) 2010-03-25
US20100298287A1 (en) 2010-11-25
WO2009093747A1 (fr) 2009-07-30
US8785460B2 (en) 2014-07-22
UY31604A1 (es) 2009-08-31
US8901141B2 (en) 2014-12-02
JP2011509923A (ja) 2011-03-31
EA201070876A1 (ru) 2011-04-29
NZ587215A (en) 2012-08-31
CL2009000116A1 (es) 2010-08-27
DOP2010000226A (es) 2010-10-15
JP5431341B2 (ja) 2014-03-05
US20090186879A1 (en) 2009-07-23
AU2009206936A1 (en) 2009-07-30
GEP20125637B (en) 2012-09-10
IL207074A0 (en) 2010-12-30
MX2010008039A (es) 2010-08-10
ECSP10010414A (es) 2010-09-30
CN101981031A (zh) 2011-02-23
CA2712347A1 (fr) 2009-07-30
EP2240485B1 (fr) 2014-10-15
ZA201005340B (en) 2011-10-26
CO6230982A2 (es) 2010-12-20

Similar Documents

Publication Publication Date Title
MA32438B1 (fr) Composés tricycliques présentant une activité antagoniste envers le facteur de libération de la corticotropine et compositions pharmaceutiques les contenant
Tale et al. The novel 3, 4-dihydropyrimidin-2 (1H)-one urea derivatives of N-aryl urea: synthesis, anti-inflammatory, antibacterial and antifungal activity evaluation
Capela et al. Design and evaluation of primaquine-artemisinin hybrids as a multistage antimalarial strategy
SI1716152T1 (sl) Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj
TW200612950A (en) Quinazolinedione derivatives as PARP inhibitors
PE20141202A1 (es) Compuesto de ciclopropanoamina
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
EA201070635A1 (ru) Соединения, ингибирующие дипептидилпептидазу-iv,способы их получения и фармацевтические композиции, содержащие их в качестве активного агента
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
EA201001842A1 (ru) Новые соединения, обладающие активностью антагонистов мускариновых рецепторов
DE602005027728D1 (de) Benzodiazepin-Derivate als ROCK-Kinasen Hemmer
DE602006014273D1 (de) Pyrazoloä3 , 4-düazepinderivate als histamin-h3-antagonisten
GEP20146025B (en) Chromenone derivatives as trpv3 antagonists
ATE481972T1 (de) Chinazolinon-derivate als vanilloid-antagonisten
DE602007005387D1 (de) Ptors
WO2008098077A3 (fr) Composés thérapeutiques
MY144635A (en) 2-oxo-1,2,4,5-tetrahydro-1,-3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
ATE455095T1 (de) Vanilloidrezeptor trpv1-antagonisten